ArticleBMC infectious diseases2026
Utility of recombinant Schistosoma bovis 22.6 kDa antigen for diagnosis of human urogenital schistosomiasis by ELISA: a cross-sectional study in Yewa North LGA, Ogun State, Nigeria.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn many endemic regions, accurately diagnosing urogenital schistosomiasis remains challenging, particularly in cases of low-intensity infection and limited laboratory capacity. Exploring antigens that cross-react between related schistosome species provides a promising alternative to conventional diagnostic approaches. Schistosoma bovis-an animal parasite closely related to S. haematobium and sharing the same Bulinus snail hosts in overlapping habitats- is a strong candidate for such studies. This work therefore assessed whether the recombinant S. bovis 22.6 kDa antigen (rSb22.6 kDa) could detect anti-schistosome antibodies in urine samples from individuals living in S. haematobium-endemic communities in Nigeria.
methodsUrine samples from 559 individuals (290 adults and 269 children; 235 males and 313 females) from four communities and schools in Yewa North Local Government Area, Ogun State, Nigeria, were collected. Samples were examined for S. haematobium eggs by microscopy, screened for anti-schistosomal antibodies using rSb 22.6 kDa ELISA, and analyzed for haematuria, leukocyturia, and proteinuria using reagent strips.
resultsPrevalence by microscopy was 13.9% (78/558), while 54.1% (299/553) of samples were seropositive by ELISA. Among ELISA-positive individuals, 29.8% had haematuria, 47.9% had leukocyturia, and 37.1% had proteinuria. Of 480 microscopy-negative individuals, 221 (46.0%) were ELISA-positive. When microscopy was used as the reference standard, the rSb 22.6 kDa-ELISA showed 46.2% sensitivity and 45.8% specificity. However, ELISA positivity correlated significantly with clinical markers of urogenital pathology (P < 0.05).
conclusionThe rSb 22.6 kDa antigen demonstrated cross-reactivity with antibodies in urine from individuals in S. haematobium-endemic communities. The high seropositivity compared to microscopy prevalence may reflect detection of low-intensity infections, past exposure with persistent antibodies, or ongoing transmission intensity in these communities. While the current performance of the assay does not support its use for individual diagnosis, it shows potential for sero-epidemiological surveillance in endemic areas. Further validation studies incorporating molecular diagnostics and longitudinal follow-up will clarify the significance of antibody positivity in the absence of detectable eggs. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.